Company Overview - Aohua Endoscopy is located in Minhang District, Shanghai, and was established on October 27, 1994. The company went public on November 15, 2021. It specializes in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The main revenue composition of Aohua Endoscopy includes: 92.35% from endoscopy equipment, 3.71% from endoscopic diagnostic consumables, 3.58% from endoscopy maintenance services, and 0.35% from leasing income [1] Stock Performance - On February 2, Aohua Endoscopy's stock fell by 5.04%, trading at 43.94 CNY per share, with a total transaction volume of 97.43 million CNY and a turnover rate of 1.60%. The total market capitalization is 5.917 billion CNY [1] Fund Holdings - Tianhong Fund has a significant holding in Aohua Endoscopy through its Tianhong Zhenxuan Health Mixed A fund (014708), which reduced its holdings by 20,100 shares in the fourth quarter, now holding 48,400 shares, accounting for 7.82% of the fund's net value [2] - The estimated floating loss for the fund today is approximately 112,800 CNY [2] Fund Performance - Tianhong Zhenxuan Health Mixed A fund was established on March 17, 2022, with a current size of 18.2122 million CNY. Year-to-date returns are 6.22%, ranking 3720 out of 9000 in its category. Over the past year, the fund has achieved a return of 38.85%, ranking 3199 out of 8193. Since inception, the fund has returned 24.87% [2]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has experienced a decline in revenue and profit, alongside significant changes in shareholder structure and financing activities [1][2][3] Group 2 - As of January 22, Aohua Endoscopy's stock price fell by 1.57%, with a trading volume of 45.86 million yuan. The financing buy-in amount was 4.40 million yuan, while the financing repayment was 3.21 million yuan, resulting in a net financing buy-in of 1.20 million yuan. The total financing and securities balance reached 111 million yuan [1] - The financing balance of Aohua Endoscopy is 111 million yuan, accounting for 1.82% of the circulating market value, which is above the 60th percentile of the past year, indicating a high level [1] - The company has a total of 5,549 shareholders as of September 30, which is an increase of 41.52% compared to the previous period, while the average circulating shares per person decreased by 29.34% [2] - For the period from January to September 2025, Aohua Endoscopy reported a revenue of 423 million yuan, a year-on-year decrease of 15.57%, and a net profit attributable to shareholders of -56.09 million yuan, a year-on-year decrease of 250.37% [2] - Aohua Endoscopy has distributed a total of 76.28 million yuan in dividends since its A-share listing, with 50.95 million yuan distributed in the last three years [3] - Among the top ten circulating shareholders, the fund "Fuguo Precision Medical Flexible Allocation Mixed A" ranks third with 5.34 million shares, an increase of 505,500 shares compared to the previous period [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has experienced a decline in both revenue and net profit, indicating potential challenges in its financial performance [2] - As of December 24, Aohua Endoscopy's stock price decreased by 0.04%, with a trading volume of 58.05 million yuan and a net financing buy of -2.62 million yuan [1] - The company's financing balance reached 125 million yuan, accounting for 2.07% of its market capitalization, which is above the 80th percentile of the past year [1] Group 2 - For the period from January to September 2025, Aohua Endoscopy reported a revenue of 423 million yuan, a year-on-year decrease of 15.57%, and a net profit attributable to shareholders of -56.09 million yuan, a significant decline of 250.37% [2] - The number of shareholders increased by 41.52% to 5,549, while the average circulating shares per person decreased by 29.34% to 24,268 shares [2] - Aohua Endoscopy has distributed a total of 76.28 million yuan in dividends since its A-share listing, with 50.95 million yuan distributed in the last three years [3]

Core Viewpoint - Aohua Endoscopy experienced a decline of 3.21% in stock price on December 23, with a trading volume of 69.16 million yuan, indicating potential investor concerns regarding the company's financial performance and market position [1]. Financing and Trading Data - On December 23, Aohua Endoscopy had a financing buy-in amount of 8.64 million yuan, with a net financing buy of 5.35 million yuan after repayments [1]. - The total financing and securities balance reached 128 million yuan, accounting for 2.11% of the circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - The company had no short selling activity on December 23, with a short selling balance of 28.72 thousand yuan, also above the 90th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Aohua Endoscopy reported a revenue of 423 million yuan, a year-on-year decrease of 15.57%, and a net profit attributable to shareholders of -56.09 million yuan, reflecting a significant decline of 250.37% [2]. - Cumulative cash dividends since the company's A-share listing amount to 76.28 million yuan, with 50.95 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 41.52% to 5,549, while the average circulating shares per person decreased by 29.34% to 24,268 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by the third-largest shareholder, with a 50.55 thousand share increase, while other funds reduced their holdings [3].

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a significant increase in its stock price, rising by 5.42% to 49.39 CNY per share, with a total market capitalization of 6.651 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's main revenue sources are: endoscopy equipment (92.35%), endoscopy diagnostic consumables (3.71%), endoscopy maintenance services (3.58%), and leasing income (0.35%) [1] Group 2 - According to data, Aohua Endoscopy is a top ten holding in the Agricultural Bank of China Fund's Aohua Specialized and New Mixed Fund (016305), which increased its holdings by 2,831 shares in the third quarter, now holding 57,300 shares, representing 2.32% of the fund's net value [2] - The Aohua Specialized and New Mixed Fund has achieved a year-to-date return of 47.01%, ranking 1,341 out of 8,148 in its category, and a one-year return of 37.65%, ranking 1,639 out of 8,053 [2] - The fund manager, Wei Gang, has been in position for 7 years and 229 days, with the fund's total asset size at 540 million CNY and a best return of 131.83% during his tenure [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a stock price increase of 5.1%, reaching 51.73 yuan per share, with a total market capitalization of 6.966 billion yuan [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] - The company is classified as a high-tech enterprise, with additional revenue sources including endoscope consumables (3.71%), maintenance services (3.58%), and leasing (0.35%) [1] Group 2 - Xiangcai Fund has a significant holding in Aohua Endoscopy, with its Xiangcai Medical Health Mixed A fund holding 18,000 shares, representing 4.8% of the fund's net value [2] - The fund has achieved a year-to-date return of 44.3%, ranking 1642 out of 8155 in its category, and a one-year return of 36.51%, ranking 2016 out of 8029 [2] - The fund manager, Zhang Quan, has been in position for 1 year and 308 days, with the fund's total assets amounting to 18.3775 million yuan [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a stock price increase of 5.3%, reaching 50.86 CNY per share, with a total market capitalization of 6.849 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] - The company is located in Minhang District, Shanghai, and was listed on November 15, 2021 [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, one fund from GF Fund Management, the GF Healthcare Stock A (004851), has entered the list, holding 1.7267 million shares, which is 1.28% of the circulating shares [2] - The GF Healthcare Stock A fund was established on August 10, 2017, and has a current scale of 5.247 billion CNY, with a year-to-date return of 19.8% [2] - The fund's performance ranks 2665 out of 4218 in its category this year, and it has achieved a cumulative return of 93.64% since inception [2] Group 3 - The fund manager of GF Healthcare Stock A is Wu Xingwu, who has been in the position for 10 years and 258 days, managing assets totaling 9.853 billion CNY [3] - During his tenure, the best fund return achieved was 105.25%, while the worst return was -37.23% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a significant increase in its stock price, rising by 5.45% to 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's main revenue sources are: endoscopy equipment (92.35%), endoscopy consumables (3.71%), endoscopy maintenance services (3.58%), and leasing income (0.35%) [1] Group 2 - Aohua Endoscopy is a significant holding in the fund managed by Agricultural Bank of China, with the Aohua Endoscopy stock representing 2.58% of the fund's net value, making it the fifth-largest holding [2] - The Agricultural Bank of China fund, named Agricultural Bank of China Specialized and New Mixed A (016305), has achieved a year-to-date return of 39.95% and ranks 1392 out of 8162 in its category [2] - The fund manager, Wei Gang, has been in charge for over 7 years, with the best fund return during his tenure being 121.47% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy experienced a stock price increase of 5.45%, reaching 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The revenue composition of Aohua Endoscopy includes 92.35% from endoscopy equipment, 3.71% from endoscopic diagnostic consumables, 3.58% from maintenance services, and 0.35% from leasing [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, ICBC Credit Suisse Fund's Aohua Medical Stock A (001717) reduced its holdings by 805,800 shares, now holding 3.0942 million shares, which is 2.3% of the circulating shares [2] - The Aohua Medical Stock A fund has achieved a year-to-date return of 26.76% and a one-year return of 20.01%, ranking 1686 out of 4218 and 2253 out of 3868 in its category, respectively [2] - The fund manager, Zhao Bei, has been in position for 10 years and 341 days, with the fund's total asset size at 16.425 billion CNY and a best return of 233% during his tenure [3]

Group 1 - The stock price of Aohua Endoscopy has declined by 1.57% to 46.25 CNY per share, with a total market capitalization of 6.228 billion CNY, and a cumulative drop of 9.46% over the last four days [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] Group 2 - Beixin Ruifeng Fund holds 100,000 shares of Aohua Endoscopy in its health lifestyle theme flexible allocation fund, representing 5.48% of the fund's net value, with a floating loss of approximately 74,000 CNY today and 483,000 CNY over the four-day decline [2] - The Beixin Ruifeng Health Lifestyle Theme Flexible Allocation Fund (001056) has a total scale of 90.1431 million CNY and has achieved a year-to-date return of 29.83% [2]